Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Jan 30, 2039method-of-use (U-4331)US 11541064
Oct 27, 2034method-of-use (U-4332)US 9345717
Oct 12, 2034method-of-use (U-4332)US 10086006

FDA exclusivities (2)

Oct 22, 2033GAINGAIN Antibiotic (5y)
Oct 22, 2028NPNP2.3y

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

Trials studying fosfomycin disodium

phase2Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial)completedn=28